UNSPSC 51332835: Acetophenazine maleate

This classification denotes a phenothiazine and antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3P5HNU5JTC. European Medicines Agency schedules Acetophenazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00255MIG. Acetophenazine maleate generally arises in the molecular formula C23H29N3O2S.2C4H4O4. The term 'acetophenazine maleate' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule acetophenazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, ACETOPHENAZINE MALEATE remains US FDA's Preferred Term for this commodity. Acetophenazine maleate bears US NLM identifiers UMLS ID C0304378 and NCI Concept Code C65210. SMILES: CC(=O)C1CC2C(CC1)SC3C(CCCC3)N2CCCN4CCN(CC4)CCO.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51332835 Acetophenazine maleate is a Commodity code that appears in state and local procurement activity focused on pharmaceutical procurement, though the recent opportunities tagged under this code do not reflect acetophenazine maleate specifically. Instead, the code surfaces within broader pharmaceutical and health-related goods solicitations, including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. State and local buyers under this code span health departments, county health systems, and cooperative purchasing alliances serving multiple jurisdictions. The work being solicited includes supply agreements for pharmaceutical products, community health initiatives requiring pharmaceutical inventory, and multi-state cooperative purchasing arrangements for generic medications and over-the-counter items through authorized wholesalers.

Activity under this code appears concentrated in the South and Midwest. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, while the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. The Texas Health and Human Services Commission issued an RFI (HHS0017013, due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs for self-insured health plans. Vendors pursuing pharmaceutical supply contracts under this code should anticipate requirements for cGMP and Drug Supply Chain Security Act compliance, relationships with authorized pharmaceutical wholesalers, comprehensive insurance coverage including commercial general liability and professional liability, and E-Verify and drug-free workplace certifications.